Types of Mesothelioma - Diffuse Pleural Mesothelioma
References
1.Elmes PC, Simpson MJC. The clinical aspects of mesothelioma. Q J Med 1976;45:427-449.[Medline]
2.Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981;8:313-320.[Medline]
3.Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.[Medline]
4.Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report of 5 cases. Arch Pathol 1931;11:385-412.
5.Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-271.
6.Butchart EG, Gibbs AR. Pleural mesothelioma. Curr Opin Oncol 1990;2:352-358.[Medline]
7.Butchart EG. Surgery of mesothelioma of the pleura. In: Roth JA, Ruckdeschel JC, Weisenburger TH, eds. Thoracic Oncology. Philadelphia: WB Saunders, 1989:566-583.
8.Wojtukiewicz MZ, Zacharski LR, Memoli VA et al. Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 1989;55:279-284.[Medline]
9.Craighead JE. Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 1987;18:544-557.[Medline]
10.Kaiser LR. New therapies in the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:383-390.[Medline]
11.Pass HI. Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma. Chest Surg Clin N Am 1994;4:497-515.[Medline]
12.Upham JW, Garlepp MJ, Musk AW et al. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995;50:887-893.[Medline]
13.Lewis RJ. Malignant pleural mesothelioma: a nonsurgical problem. In: Kittle CF, ed. Current Controversies in Thoracic Surgery. Philadelphia: WB Saunders, 1986:61-67.
14.Butchart EG, Ashcroft T, Barnsley WC et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 1976;31:15-24.[Abstract]
15.Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152.[Abstract]
16.Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-825.[Abstract/Free Full Text]
17.Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.[Abstract/Free Full Text]
18.International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-1128.[Abstract]
19.Pass HI, Temeck BK, Kranda K et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-318.[Abstract/Free Full Text]
20.Patz EF, Shaffer K, Piwnica-Worms DR et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. Am J Radiol 1992;159:961-966.[Abstract]
21.Conlon KC, Rusch VW, Gillern S. Laparoscopy: an important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol 1996;3:489-494.[Abstract]
22.Gilron J, Richardi G, Fajadet P et al. New imaging modalities of mesothelioma (CT versus MRI). Eur Respir J 1994;7(suppl 18):131s.
23.Knuuttila A, Halme M, Kivisaari L et al. The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma. Lung Cancer 1998;22:215-225.[Medline]
24.Boraschi P, Neri S, Braccini G et al. Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases. Scand J Work Environ Health 1999;25:18-23.[Medline]
25.Sugarbaker DJ. Extrapleural pneumonectomy is the procedure of choice for early stage malignant mesothelioma. American Association for Thoracic Surgery, 79th annual meeting, April 1999.
26.Sugarbaker DJ, Garcia JP, Richards WG et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural pleural mesothelioma. Ann Surg 1996;224:288-296.[Medline]
27.Astiyk O, Picat-Joossen D, Viallat JR et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998;83:2099-2104.[Medline]
28.Hilaris BS, Nori D, Kwong E et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 1984;10:325-331.[Medline]
29.Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:367-372.[Medline]
30.Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.[Medline]
31.HSkkinen AM, Laasonen A, Linnainmaa K et al. Radiosensitivity of mesothelioma cell lines. Acta Oncol 1996;35:451-456.[Medline] 32.Kutcher GJ, Kestler C, Greenblatt D et al. Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 1987;13:1747-1752.[Medline]
33.Holsti LR, Pyrhonen S, Kajanti M et al. Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol 1997;36:397-405.[Medline]
34.Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionising radiation in antitumour therapy. Nature 1998;394:287-291.[Medline]
35.De Graaf-Strukowska L, van der Zee J, van Putten W et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511-516.[Medline]
36.Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994;38:212-214.[Medline]
37.Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol 1991;3:315-317.
38.Low EM, Khoury GG, Matthews AW et al. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol 1995;7:317-318.
39.Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-758.[Abstract]
40.Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113:66S-73S.[Abstract] 41.Hunt KJ, Longton G, Williams MA et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996;109:1239-1242.[Abstract]
42.Hoffman KR. Paclitaxel and carboplatin combination chemotherapy is an effective palliative treatment for malignant mesothelioma. Proc Annu Meet Am Soc Clin Oncol 1996;15:A1428.
43.Chahinian AP, Mandeli JP, Gluck H et al. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 1998;67:104-111.[Medline]
44.Emri S, Koc Y, O'Brien MC et al. Taxol and arginine butyrate exert additive antiproliferative effects on human mesothelioma cells. Proc Annu Meet Am Soc Clin Oncol 1994;13:A316.
45.Herscher LL, Hahn SM, Kroog G et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 1998;16:635-641.[Abstract]
46.Galen P. Hyperthermia and chemotherapy. Adv Exp Med Biol 1990;267:209-216.[Medline]
47.Miller RC, Richards M, Baird C et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994;10:89-99.[Medline]
48.Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989;27:621-627.[Medline]
49.Ratto GB, Civalleri D, Esposito M et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma. J Thorac Cardiovasc Surg 1999;117:759-765.[Abstract/Free Full Text]
50.Ma GY, Bartlett DL, Reed E et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the
treatment of peritoneal mesothelioma. Cancer J Sci Am 1997;3:174-179.[Medline]
51.Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982;61:1007-1009.[Medline]
52.Bielefeldt-Ohmann H, Jarick AG, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol 1996;178:369-378.[Medline]
53.Donington JS, Mew DJ, Pass HI. Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies. Surg Oncol 1995;4:175-185.[Medline]
54.Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL et al. The potential for interferon-alpha therapy in mesothelioma. J Interferon Cytokine Res 1995;5:213-223.
55.Ardizzoni A, Pennucci MC, Castagneto B et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994;17:80-82.[Medline]
56.Christmas TI, Manning LS, Garlepp MJ et al. Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 1993;13:9-12.[Medline]
57.Tansan S, Emri S, Selcuk T et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994;51:348-351.[Medline]
58.Purohit A, Moreau L, Dietemann A et al. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 1998;22:119-125.[Medline]
59.O'Reilly EM, Ilson DH, Saltz LB et al. A phase II trial of interferon-alpha 2a and carboplatin in malignant mesothelioma. Cancer Invest 1999;17:195-200.[Medline]
60.Nano R, Capelli E, Civallero M et al. Effects of interleukin-2 for the treatment of malignant mesothelioma. Oncol Rep 1998;5:489-492.[Medline]
61.Robinson BW, Mukherjee SA, Davidson A et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998;21:211-217.[Medline]
62.Boutin C, Nussbaum E, Monnet I et al. Intrapleural treatment with recombinant gamma-interferon in early
stage malignant pleural mesothelioma. Cancer 1994;74:2460-2467.[Medline]
63.Monti G, Jaurant MC, Monnet I et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994;54:4419-4423.[Abstract]
64.Smythe WR, Hwang HC, Elshami AA et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995;222:78-86.[Medline]
65.Escandi MC, van Someren GD, Vincent AJ et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997;4:280-287.[Medline]
66.Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998;12:553-568.[Medline]
67.Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092.[Medline]
68.Lanuti M, Gao GP, Force SD et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999;10:463-475.[Medline]
69.Batra RK, Olsen JC, Hoganson DK et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997;272:11736-11743.[Abstract/Free Full Text]
70.Frizelle SP, Grim J, Zhou J et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16:3087-3095.[Medline]
71.Balsara BR, Bell DW, Sonoda G et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999;59:450-454.[Abstract/Free Full Text]
72.Shivapurkar N, Virmani AK, Wistuba II et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999;5:17-23.[Abstract/Free Full Text]
73.Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 1999;14:181-188.[Medline]
74.Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998;150:146S-156S.
75.Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-328.[Medline]
76.Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996;14:329-334.[Medline]
77.Feins RH, Hilf R, Ross H et al. Photodynamic therapy for human malignant mesothelioma in the nude mouse. J Surg Res 1990;49:311-314.[Medline]
78.Foster TH, Gibson SL, Raubertas RF. Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light. Br J Cancer 1996;73:933-936.[Medline]
79.Ris HB, Giger A, Hof VI et al. Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma. Eur J Cardiothorac Surg 1997;12:542-548.[Abstract]
80.Ris HB, Altermatt HJ, Stewart CM et al. Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer 1993;55:245-249.[Medline]
81.Ris HB, Altermatt HJ, Nachbur B et al. Effect of drug-light interval on photodynamic therapy with metatetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 1993;53:141-146.[Medline]
82.Stewart F, Baas P, Star W. What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Radiother Oncol 1998;48:233-248.[Medline]
83.Takita H, Mang TS, Loewen GM et al. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann Thorac Surg 1994;58:995-998.[Abstract]
84.Moskal TL, Dougherty TJ, Urschel JD et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998;66:1128-1133.[Abstract]
85.Pass HI, Temeck BK, Kranda K et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997;4:628-633.[Abstract]
86.Pass HI, Delaney TF, Tochner Z et al. Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1994;1:28-37.[Abstract]
87.Leketich JD, Westkaemper J, Sommers KE et al. Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Ann Thorac Surg 1996;62:283-284.[Abstract/Free Full Text]
88.Temeck BK, Pass HI. Esophagopleural fistula: a complication of photodynamic therapy. South Med J 1995;88:271-274.[Medline]
89.Canto A, Guijarro R, Arnau A et al. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac Cardiovasc Surg 1997;45:16-19.[Medline]
90.Patz EF. Malignant pleural effusions: recent advances and ambulatory sclerotherapy. Chest 1998;113:74S-77S.[Abstract]
Mesothelioma Information
Malignant mesothelioma is a rare type of cancer that affects the serous membrane that lines three of the body’s largest cavities: the pleura (lung cavity), the peritoneum (abdominal cavity) and the pericardium (heart sac). There are three distinct types of mesothelioma, each one affecting a different section of mesothelial tissue:
- Pleural mesothelioma
- Peritoneal mesothelioma
- Pericardial mesothelioma
Mesothelioma symptoms vary dependent on the type of mesothelioma one is suffering from, but can typically include chronic chest pain, fever, nausea and abnormal breathing.
Mesothelioma treatment options have thus far been unable to thwart the deadly disease, though researchers believe that scientific advances are paving the way to a future breakthrough.